all the information, none of the junk | biotech • healthcare • life sciences

Gilead Sciences CEO Milligan to Depart for “New Opportunities”

John Milligan will step down as president and CEO of Gilead Sciences (NASDAQ: GILD) at the end of the year, the Foster City, CA company announced Wednesday. Milligan’s departure will end a 28-year career with the company. In a prepared statement, Milligan said he would move on to “new and different opportunities.” Milligan will also leave his seat on Gilead’s board of directors. A search for Milligan’s successor is underway. Gilead also announced that board chairman John Martin will step down. Martin will leave the board when a new CEO joins Gilead.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com Follow @frankvinluan